Golden
Karyopharm Therapeutics

Karyopharm Therapeutics

A pharmaceutical company that develops drugs to treat cancer and other major disease

All edits

Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 10:29 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 Jun 2019 10:28 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 Jun 2019 9:54 pm
Edits made to:
Infobox (+1 properties)
Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+2 properties)

Infobox

Edits on 2 Apr 2019
Dawson Sewell
Dawson Sewell edited on 2 Apr 2019 5:29 pm
Edits made to:
Infobox (+1 properties)

Infobox

Industry
Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 10:04 pm
Edits made to:
Infobox (+4 properties)
Timeline (+2 events) (+301 characters)
Article (+849/-487 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)

Article

Karyopharm Therapeutics is a publicly traded, clinical-stage pharmaceutical company based in Newton, Massachusetts. It focuses on the discovery and development of first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, which was developed to address a central mechanism of oncogenesis via the inhibition of exportins, specifically XPO1.

Karyopharm Therapeutics is a publicly traded, clinical-stage pharmaceutical company based in Newton, Massachusetts that was founded in 2008 by Ronald A. DePinho and Sharon Shacham.

...

The company focuses on the discovery and development of first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, which was developed to address a central mechanism of oncogenesis via the inhibition of exportins, specifically XPO1.

Products

...

Funding

Series A

On November 2, 2011 Karyopharm Therapeutics completed their series A funding round with $10 million in funding from Chione. 

Series B

On May 20, 2017 Karyopharm Therapeutics completed their series B funding round with $48.5 million in capital from Delphi Ventures. 



Infobox

Date incorporated
2008

Categories

Related Topics

Timeline

May 20, 2017

Series B funding round

On May 20, 2017 Karyopharm Therapeutics completed their series C funding round with $48.5 million in capital from Delphi Ventures. 

November 2, 2011

Series A funding round

On November 2, 2011 Karyopharm Therapeutics completed their series A funding round with $10 million in funding from Chione. 

Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:12 pm
Edits made to:
Infobox (+2/-2 properties)
Edits on 18 Jan 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 18 Jan 2019 2:41 am
Edits made to:
Article (+4/-4 characters)

Article

Verdinexor is intended to be a potential oral antiviral treatment for influenza. It is also being evaluated for the treatment of lymphomas and other cancers in dogs. KPT-9274 is an orally bioavailable small molecule that is a non-competitive dual modulator of PAK4PAK4 and NAMPT for the treatment of patients with advanced solid malignancies or non-Hodgkin's Lymphoma. 

Edits on 16 Jan 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 16 Jan 2019 9:56 pm
Edits made to:
Article (+18/-18 characters)

Article

Karyopharm's leading product candidate is Selinexor, an oral, reversible SINE that specifically blocks XPO1. It is being evaluated in multiple Phase 2 and 3 clinical trials in patients with relapsed or refractory hematological and solid tumor malignancies. Selinexor has been granted Orphan Drug Designation in both the US and the EU in multiple myeloma. It is also being investigated in clinical Phase 3 clinical studies for advanced unresectable dedifferentiated liposarcoma and endometrial cancerendometrial cancer. Karyopharm is preparing for its first potential U.S. commercial launch with Selinexor sometime in 2019.

Edits on 15 Jan 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 Jan 2019 2:13 pm
Edits made to:
Article (+21/-21 characters)

Article

Karyopharm Therapeutics is a publicly traded, clinical-stage pharmaceutical company based in Newton, MassachusettsNewton, Massachusetts. It focuses on the discovery and development of first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, which was developed to address a central mechanism of oncogenesis via the inhibition of exportins, specifically XPO1.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 Jan 2019 2:12 pm
Edits made to:
Article (+4/-4 characters)

Article

Karyopharm Therapeutics is a publicly traded, clinical-stage pharmaceutical company based in Newton, Massachusetts. It focuses on the discovery and development of first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, which was developed to address a central mechanism of oncogenesis via the inhibition of exportins, specifically XPO1XPO1.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 Jan 2019 2:11 pm
Edits made to:
Article (+17/-17 characters)

Article

Other products in the company's pipeline include, Eltanexor, Verdinexor, and KPT-9274. Eltanexor is an investigational second-generation SINE compound that is designed to selectively block XPO1. Similar to Selinexor, it is also intended to serve as a treatment for cancer indications, including myelodysplastic syndrome, colorectal cancercolorectal cancer, and castrate-resistant prostate cancer.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 15 Jan 2019 2:11 pm
Edits made to:
Article (+15/-15 characters)

Article

Other products in the company's pipeline include, Eltanexor, Verdinexor, and KPT-9274. Eltanexor is an investigational second-generation SINE compound that is designed to selectively block XPO1. Similar to Selinexor, it is also intended to serve as a treatment for cancer indications, including myelodysplastic syndrome, colorectal cancer, and castrate-resistant prostate cancerprostate cancer.

Edits on 12 Jan 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 12 Jan 2019 8:47 pm
Edits made to:
Infobox (+2/-1 properties)
Article (+1838 characters)
People (+11 rows) (+22 cells) (+497 characters)
Further reading (+2 rows) (+8 cells) (+413 characters)

Article

Karyopharm Therapeutics is a publicly traded, clinical-stage pharmaceutical company based in Newton, Massachusetts. It focuses on the discovery and development of first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company specializes in oral Selective Inhibitor of Nuclear Export (SINE) technology, which was developed to address a central mechanism of oncogenesis via the inhibition of exportins, specifically XPO1.



Karyopharm's leading product candidate is Selinexor, an oral, reversible SINE that specifically blocks XPO1. It is being evaluated in multiple Phase 2 and 3 clinical trials in patients with relapsed or refractory hematological and solid tumor malignancies. Selinexor has been granted Orphan Drug Designation in both the US and the EU in multiple myeloma. It is also being investigated in clinical Phase 3 clinical studies for advanced unresectable dedifferentiated liposarcoma and endometrial cancer. Karyopharm is preparing for its first potential U.S. commercial launch with Selinexor sometime in 2019.

Other products in the company's pipeline include, Eltanexor, Verdinexor, and KPT-9274. Eltanexor is an investigational second-generation SINE compound that is designed to selectively block XPO1. Similar to Selinexor, it is also intended to serve as a treatment for cancer indications, including myelodysplastic syndrome, colorectal cancer, and castrate-resistant prostate cancer.

...

Verdinexor is intended to be a potential oral antiviral treatment for influenza. It is also being evaluated for the treatment of lymphomas and other cancers in dogs. KPT-9274 is an orally bioavailable small molecule that is a non-competitive dual modulator of PAK4 and NAMPT for the treatment of patients with advanced solid malignancies or non-Hodgkin's Lymphoma. 

People

Name
Role
Related Golden topics

Anand Varadan

Executive VP & Chief Commercial Officer



Brian Austad

Senior VP, Pharmaceutical Sciences



Christopher B. Primiano

Executive VP, Chief Business Officer, General Counsel, & Secretary



Ian Karp

VP, Investor and Public Relations



Jatin Shah

Senior VP, Clinical Development



Joan Wood

Chief Human Resource Officer



Michael Falvey

Executive VP, CFO, & Treasurer



Michael G. Kauffman

CEO



Ran Frenkel

Chief Development Operations Officer



Ronit Milstein

VP, Operations



Sharon Shacham

President & Chief Scientific Officer



Further reading

Title
Author
Link
Type

Karyopharm Therapeutics Announces Management Change

Karyopharm Therapeutics Inc.

Web

Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

CNBC

Web

Infobox

Edits on 9 Jan 2019
Golden AI
Golden AI edited on 9 Jan 2019 10:33 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:10 am
Edits made to:
Infobox (+4 properties)
People (+4 rows) (+8 cells) (+88 characters)

People

Name
Role
Related Golden topics

Ari Shamiss

Employee



Jonathan Sands

Investor



Sharon Shechter

Employee



Susie Harrington

Employee



Infobox

Edits on 18 Sep 2018
Golden AI"Import data from spreadsheet"
Golden AI edited on 18 Sep 2018 7:59 pm
Edits made to:
Categories (+1 topics)

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:53 pm

Infobox

Edits on 16 Jul 2018
Golden AI"Update markets in infobox"
Golden AI edited on 16 Jul 2018 11:38 pm

Infobox

Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:51 pm